Publicaciones científicas

38 Publicaciones científicas disponibles

  • Performance Comparison of Two Next-Generation Sequencing Panels to Detect Actionable Mutations in Cell-Free DNA in Cancer Patients

    28 de julio de 2020 | Revista: Clinical Chemistry and Laboratory Medicine

    Mónica Macías  (1) , Eva Cañada-Higueras  (2) , Estibaliz Alegre  (1, 3) , Arancha Bielsa  (2) , Javier Gracia  (2) , Ana Patiño-García  (2, 3, 4) , Roser Ferrer-Costa  (5) , Teresa Sendino  (1) , María P Andueza  (6) , Beatriz Mateos (1) , Javier Rodríguez  (3, 6) , Jesús Corral  (2) , Alfonso Gúrpide  (3, 6) , José M Lopez-Picazo  (3, 6) , Jose L Perez-Gracia  (3, 6) , Ignacio Gil-Bazo  (3, 6, 7, 8) , Gorka Alkorta-Aranburu (2) , Álvaro González  (1, 3)

    (1) Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIMA LAB Diagnostics Universidad de Navarra, Pamplona, Spain.
    (3) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Biochemistry, Hospital Universitari Vall D'Hebron, Universitat Autònoma De Barcelona, Barcelona, Spain.
    (6) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (8) Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.


  • Neoadjuvant therapy for locally advanced gastric cancer patients

    9 de mayo de 2020 | Revista: PLoS One

    Patricia Martin-Romano (1), Belén P Solans (2), David Cano (3), Jose Carlos Subtil (4), Ana Chopitea (1), Leire Arbea (1), Maria Dolores Lozano (5), Eduardo Castanon (1), Iosune Baraibar (1), Diego Salas (1), Jose Luis Hernandez-Lizoain (6), Iñaki F Trocóniz (2), Javier Rodriguez (1)

    (1) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Universidad de Navarra, Pamplona, Spain.
    (3) Department of Radiology, Clinica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Gastroenterology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Surgical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.


  • Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    20 de febrero de 2019 | Revista: Scientific Reports

    Borrero-Palacios A (1), Cebrián A (2), Gómez Del Pulgar MT (1), García-Carbonero R (3), García P (4), Aranda E (5), Elez E (6), López-López R (7), Cervantes A (8), Valladares M (9), Nadal C (10), Viéitez JM (11), Guillén-Ponce C (12), Rodríguez J (13), Hernández I (14), García JL (15), Vega-Bravo R (16), Puime-Otin A (16), Martínez-Useros J (1), Del Puerto-Nevado L (1), Rincón R (1), Rodríguez-Remírez M (1), Rojo F (16), García-Foncillas J (17).

    (1) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (2) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (3) Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain.
    (4) Medical Oncology Department, Hospital Gral. Univ. Gregorio Marañón, Madrid, Spain.
    (5) Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
    (6) Medical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain.
    (7) Medical Oncology Department, Complexo Hospitalario Universitario Santiago de Compostela, Galicia, Spain.
    (8) Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
    (9) Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Galicia, Spain.
    (10) Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
    (11) Medical Oncology Department, Hospital Universitario Central de Asturias, Asturias, Spain.
    (12) Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
    (13) Medical Oncology Department, Clínica Universitaria de Navarra, Navarra, Spain.
    (14) Medical Oncology Department, Complejo Hospitalario de Navarra, Navarra, Spain.
    (15) Oncology, Medical Unit, Merck S.L, an affiliate of Merck KGaA, Darmstadt, Germany.
    (16) Anatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (17) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.


  • Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors

    28 de septiembre de 2018 | Revista: Hepatic Oncology

    Zubiri L (1,1), Bilbao JI (2,2), Rodríguez J (1,1), Sangro B (3,3)

    (1) Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Interventional Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) Liver Unit (HPB Oncology Area), Clínica Universidad de Navarra, Pamplona, Spain.